NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Finnrick
Free Test
← PT-141 vendors

NexaphPT-141

3 testslatest 28 Apr 2026
Visit websitenexaph.comMonitor this vendor24/7 safety alerts · Finnrick Gold
Peptide testing

Ordered PT-141 from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
+7 more ↓
72%
Finnrick rating
#10 of 47 PT-141 vendors
3 of 3 classifiable tests passed
natural 100% · customers 4.4★ (3)
methodology · Purity focus
Finnrick analysis · PT-141

Nexaph's purity-focus evidence is strongest around GHK-Cu and a recently improving Retatrutide lane, while Tesamorelin and Semaglutide carry the clearest recurring misses. The catalog is dispersed rather than uniform, with recent high-volume testing but uneven batch documentation and several trajectories still dependent on newer cleaner samples.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Nexaph's public pages point to Shanghai Nexa Pharma Co, Nevis terms, and an Indiana operating footprint without resolving the legal counterparty. The report maps shared COA infrastructure, sister-brand trails, crypto rails, and a documented batch-sterility thread.

39 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
16 rated · tap to focus
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
12
2
KLOW
$5.72
80%
3
3
Tirzepatide
$1.13
77%
65
4
Retatrutide
$2.46
75%
107
5
PT-141selected
-
72%
3
6
BPC-157
$1.51
64%
21
7
Ipamorelin
$1.30
60%
10
8
Cagrilintide
$3.50
51%
13
9
CJC-IPA
$3.96
45%
1
10
Tesamorelin
$2.88
37%
30
11
TB-500
$1.61
37%
7
12
Sermorelin
-
36%
3
13
CJC-1295
$3.40
35%
9
14
Semaglutide
$1.90
35%
15
15
MOTS-c
$1.88
29%
6
16
NAD+
$0.04
25%
3
Contact channels
2 channels on file
Websitenexaph.comEmailcain@nexaph.com
Rating trend
PT-141 from this vendor, after each test
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%10 Sep 2025: 57%20 Feb 2026: 67%28 Apr 2026: 70%12 Nov 2026: current 72%57%67%72%Sep 25Nov 26
Showing PT-141 tests only
Nexaph PT-141 test history
3 tests · 3 pass · 0 fail· Purity focus
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
28 Apr 2026Pass
uryr26h
Tested
lab nameView COA
20 Feb 2026Pass
f35zxjy
Tested
lab nameView COA
10 Sep 2025Pass
fx68pdv
Tested
lab nameView COA

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 16 peptides and 308 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (21 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
0 corrections
No corrections.
Peptide testing

Ordered PT-141 from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply